Search Results - "Litiere, Saskia"

Imaging endpoints for clinical trial use: a RECIST perspective by Litière, Saskia, Bogaerts, Jan

“…Twenty years after its initial introduction, Response Evaluation Criteria in Solid Tumors (RECIST) remains today a unique standardized tool allowing uniform…”
Get full text

Kidney function assessment for eligibility in clinical cancer trials – Data from the European Organisation for Research and Treatment of Cancer by Puhr, Hannah C., Xenophontos, Eleni, Giraut, Anne, Litière, Saskia, Boone, Luc, Bogaerts, Jan, Collienne, Maike, Preusser, Matthias

“…There is no consensus on how to estimate kidney function for the assessment of eligibility in clinical cancer trials. We recalculated the creatinine clearance…”
Get full text

Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals by D’Ambrosio, Lorenzo, Litière, Saskia, Stacchiotti, Silvia, Gronchi, Alessandro

Get full text

Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma – An analysis of the EORTC 62012 study of the EORTC STBSG by Grünwald, Viktor, Litière, Saskia, Young, Robin, Messiou, Christina, Lia, Michela, Wardelmann, Eva, van der Graaf, Winette, Gronchi, Alessandro, Judson, Ian

“…Abstract Background Anthracycline-based chemotherapy remains the mainstay of first-line treatment in metastatic or advanced soft-tissue sarcoma (STS). Age,…”
Get full text

Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials by Vos, Melissa, Sleijfer, Stefan, Litière, Saskia, Touati, Nathan, Duffaud, Florence, van der Graaf, Winette T, Gelderblom, Hans

“…There is an unmet need for markers predicting the outcome of patients with advanced soft tissue sarcoma (STS) treated with pazopanib. Since toxicity might be…”
Get more information

EORTC 2238 "De-Escalate": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors by Grisay, Guillaume, Turco, Fabio, Litiere, Saskia, Fournier, Béatrice, Patrikidou, Anna, Gallardo, Enrique, McDermott, Ray, Alanya, Ahu, Gillessen, Silke, Tombal, Bertrand

“…The landscape of treating metastatic prostate cancer has evolved with the addition of Androgen Receptor pathway inhibitor (ARPI) to Androgen Deprivation…”
Get full text

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial by Ignatiadis, Michail, Rack, Brigitte, Rothé, Francoise, Riethdorf, Sabine, Decraene, Charles, Bonnefoi, Hervé, Dittrich, Christian, Messina, Carlo, Beauvois, Melanie, Trapp, Elisabeth, Goulioti, Theodora, Tryfonidis, Konstantinos, Pantel, Klaus, Repollet, Madeline, Janni, Wolfgang, Piccart, Martine, Sotiriou, Christos, Litiere, Saskia, Pierga, Jean-Yves

“…Abstract There is increasing evidence that breast cancer evolves over time under the selection pressure of systemic treatment. Today, treatment decisions in…”
Get full text

Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study by Verschoor, Arie Jan, Litière, Saskia, Marréaud, Sandrine, Judson, Ian, Toulmonde, Maud, Wardelmann, Eva, LeCesne, Axel, Gelderblom, Hans

“…Doxorubicin based chemotherapy is standard first line treatment for patients with soft tissue sarcoma. Currently several options to improve survival after…”
Get full text

The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database by Litière, Saskia, de Vries, Elisabeth G.E, Seymour, Lesley, Sargent, Dan, Shankar, Lalitha, Bogaerts, Jan

“…Abstract Purpose Progressive disease (PD) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 is defined as growth of measurable target lesions,…”
Get full text

The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics by Menis, Jessica, Litière, Saskia, Tryfonidis, Konstantinos, Golfinopoulos, Vassilis

“…Cancer immunotherapy has had a major impact on the established paradigms of drug development and clinical trial research. The innovative mechanism of action of…”
Get full text

The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community by Liu, Yan, Litière, Saskia, de Vries, Elisabeth GE, Sargent, Daniel, Shankar, Lalitha, Bogaerts, Jan, Seymour, Lesley

“…Abstract Purpose With the increasing use of novel targeted agents and the development of high imaging techniques, response evaluation criteria in solid tumour…”
Get full text

Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study by Constantinidou, Anastasia, Sauve, Nicolas, Stacchiotti, Silvia, Blay, Jean-Yves, Vincenzi, Bruno, Grignani, Giovanni, Rutkowski, Piotr, Guida, Michele, Hindi, Nadia, Klein, Alexander, Thibaud, Valentin, Sufliarsky, Jozef, Desar, Ingrid, Steeghs, Neeltje, Litiere, Saskia, Gelderblom, Hans, Jones, Robin L

“…IntroductionAngiosarcomas constitute approximately 2% to 3% of all soft tissue sarcomas, are characterised by an aggressive clinical behaviour and poor…”
Get full text

A Note on the Indeterminacy of the Random-Effects Distribution in Hierarchical Models by Alonso, Ariel, Litière, Saskia, Laenen, Annouschka

“…Hierarchical models are regularly used for the analysis of longitudinal or clustered data. The estimators and inferential procedures are frequently derived…”
Get full text

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics by Seymour, Lesley, Prof, Bogaerts, Jan, PhD, Perrone, Andrea, MD, Ford, Robert, MD, Schwartz, Lawrence H, Prof, Mandrekar, Sumithra, Prof, Lin, Nancy U, MD, Litière, Saskia, PhD, Dancey, Janet, Prof, Chen, Alice, MD, Hodi, F Stephen, Prof, Therasse, Patrick, MD, Hoekstra, Otto S, Prof, Shankar, Lalitha K, MD, Wolchok, Jedd D, MD, Ballinger, Marcus, PhD, Caramella, Caroline, MD, de Vries, Elisabeth G E, Prof

“…Summary Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour…”
Get full text

RECIST 1.1—Update and clarification: From the RECIST committee by Schwartz, Lawrence H, Litière, Saskia, de Vries, Elisabeth, Ford, Robert, Gwyther, Stephen, Mandrekar, Sumithra, Shankar, Lalitha, Bogaerts, Jan, Chen, Alice, Dancey, Janet, Hayes, Wendy, Hodi, F. Stephen, Hoekstra, Otto S, Huang, Erich P, Lin, Nancy, Liu, Yan, Therasse, Patrick, Wolchok, Jedd D, Seymour, Lesley

“…Abstract The Response Evaluation Criteria in Solid Tumours (RECIST) were developed and published in 2000, based on the original World Health Organisation…”
Get full text

Testing for misspecification in generalized linear mixed models by Abad, Ariel Alonso, Litière, Saskia, Molenberghs, Geert

“…Generalized linear mixed models have become a frequently used tool for the analysis of non-Gaussian longitudinal data. Estimation is often based on maximum…”
Get full text

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial by Judson, Ian, Prof, Verweij, Jaap, Prof, Gelderblom, Hans, Prof, Hartmann, Jörg T, Prof, Schöffski, Patrick, Prof, Blay, Jean-Yves, Prof, Kerst, J Martijn, PhD, Sufliarsky, Josef, Prof, Whelan, Jeremy, Prof, Hohenberger, Peter, Prof, Krarup-Hansen, Anders, MD, Alcindor, Thierry, Prof, Marreaud, Sandrine, MD, Litière, Saskia, PhD, Hermans, Catherine, Fisher, Cyril, Prof, Hogendoorn, Pancras C W, Prof, dei Tos, A Paolo, Prof, van der Graaf, Winette T A, Prof

“…Summary Background Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide—which have been used to treat soft-tissue…”
Get full text

Statistical models versus machine learning for competing risks: development and validation of prognostic models by Kantidakis, Georgios, Putter, Hein, Litière, Saskia, Fiocco, Marta

“…In health research, several chronic diseases are susceptible to competing risks (CRs). Initially, statistical models (SM) were developed to estimate the…”
Get full text

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial by DONKER, Mila, LITIERE, Saskia, RUTGERS, Emiel J. T, BIJKER, Nina, WERUTSKY, Gustavo, JULIEN, Jean-Pierre, FENTIMAN, Ian S, AGRESTI, Roberto, ROUANET, Philippe, DE LARA, Christine Tunon, BARTELINK, Harry, DUEZ, Nicole

“…Adjuvant radiotherapy (RT) after a local excision (LE) for ductal carcinoma in situ (DCIS) aims at reduction of the incidence of a local recurrence (LR). We…”
Get full text

Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial by Litière, Saskia, PhD, Werutsky, Gustavo, MD, Fentiman, Ian S, MD, Rutgers, Emiel, Prof, Christiaens, Marie-Rose, Prof, Van Limbergen, Erik, Prof, Baaijens, Margreet HA, MD, Bogaerts, Jan, PhD, Bartelink, Harry, Prof

“…Summary Background The EORTC 10801 trial compared breast-conserving therapy (BCT) with modified radical mastectomy (MRM) in patients with tumours 5 cm or…”
Get full text